Biomarker-guided rTMS for Treatment Resistant Depression — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Biomarker-guided rTMS for Treatment Resistant Depression — Stella

Home/Treatment Resistant Depression/

View on ClinicalTrials.gov

Recruiting

Back to Treatment Resistant Depression trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(2 sites)

United States

Stanford University, Stanford, California

Weill Cornell Medicine, New York, New York

Key details

Phase

Large-scale testing

Sponsor

Weill Medical College of Cornell University

Collaborators

National Institute of Mental Health (NIMH), Stanford University

Enrollment target

~348 participants

Started

September 2021

Primary completion

April 2027

Age range

22 Years – 65 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.